Skip to main content

Table 3 Trial construct 2—disease modification trial. Power to detect an expected 1.85-point difference in ADAS-cog change in the planned sample (n = 280)

From: Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study

Trial modification

Linear mixed effects model: categorical time

Linear mixed effects model: continuous time

Student’s t test

Original t test (for reference)

Scenario 1

.42

.40

.19

.82

Scenario 2

.71

.67

.56

.82

Scenario 3

.75

.71

.64

.82